News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
93,450 Results
Type
Article (6824)
Company Profile (39)
Press Release (86587)
Section
Business (27839)
Career Advice (128)
Deals (4008)
Drug Delivery (34)
Drug Development (14174)
Employer Resources (12)
FDA (2877)
Job Trends (2124)
News (49436)
Policy (6025)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (427)
Accelerated approval (1)
Adcomms (7)
Allergies (30)
Alliances (9050)
ALS (13)
Alzheimer's disease (260)
Antibody-drug conjugate (ADC) (40)
Approvals (2882)
Artificial intelligence (38)
Autoimmune disease (8)
Automation (3)
Bankruptcy (19)
Best Places to Work (1806)
BIOSECURE Act (16)
Biosimilars (89)
Biotechnology (26)
Bladder cancer (20)
Brain cancer (6)
Breast cancer (50)
Cancer (434)
Cardiovascular disease (19)
Career advice (111)
Career pathing (3)
CAR-T (20)
Cell therapy (82)
Cervical cancer (3)
Clinical research (11552)
Collaboration (180)
Compensation (40)
Complete response letters (9)
COVID-19 (544)
CRISPR (5)
C-suite (48)
Cystic fibrosis (13)
Data (413)
Denatured (2)
Depression (5)
Diabetes (35)
Diagnostics (574)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (22)
Drug pricing (26)
Drug shortages (1)
Duchenne muscular dystrophy (25)
Earnings (9491)
Editorial (5)
Employer branding (3)
Employer resources (10)
Events (11869)
Executive appointments (112)
FDA (3202)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (140)
Gene editing (24)
Generative AI (5)
Gene therapy (78)
GLP-1 (107)
Government (1311)
Grass and pollen (1)
Guidances (11)
Healthcare (1985)
Huntington's disease (2)
IgA nephropathy (2)
Immunology and inflammation (37)
Indications (8)
Infectious disease (577)
Inflammatory bowel disease (46)
Inflation Reduction Act (5)
Influenza (15)
Intellectual property (12)
Interviews (11)
IPO (1842)
IRA (13)
Job creations (389)
Job search strategy (108)
Kidney cancer (2)
Labor market (2)
Layoffs (55)
Legal (564)
Liver cancer (13)
Lung cancer (76)
Lymphoma (25)
Management (2)
Manufacturing (100)
MASH (10)
Medical device (1202)
Medtech (1203)
Mergers & acquisitions (2257)
Metabolic disorders (82)
Multiple sclerosis (15)
NASH (2)
Neurodegenerative disease (16)
Neuropsychiatric disorders (1)
Neuroscience (329)
NextGen: Class of 2025 (705)
Non-profit (350)
Northern California (459)
Now hiring (10)
Obesity (30)
Opinion (46)
Ovarian cancer (20)
Pain (8)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (28)
Patient recruitment (19)
Peanut (21)
People (8006)
Pharmaceutical (11)
Pharmacy benefit managers (3)
Phase I (3802)
Phase II (4813)
Phase III (4231)
Pipeline (278)
Podcasts (7)
Policy (39)
Postmarket research (298)
Preclinical (1476)
Press Release (66)
Prostate cancer (17)
Psychedelics (5)
Radiopharmaceuticals (37)
Rare diseases (68)
Real estate (918)
Recruiting (4)
Regulatory (4769)
Reports (11)
Research institute (391)
Resumes & cover letters (11)
RNA editing (1)
RSV (10)
Schizophrenia (11)
Series A (32)
Series B (13)
Service/supplier (3)
Sickle cell disease (7)
Southern California (465)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (577)
State (1)
Stomach cancer (3)
Supply chain (9)
The Weekly (5)
United States (3965)
Vaccines (181)
Venture capitalists (4)
Webinars (1)
Weight loss (14)
Women's health (3)
Date
Today (47)
Last 7 days (177)
Last 30 days (564)
Last 365 days (6408)
2025 (1610)
2024 (6549)
2023 (7001)
2022 (9175)
2021 (9549)
2020 (8250)
2019 (5899)
2018 (4586)
2017 (5102)
2016 (4663)
2015 (5320)
2014 (3748)
2013 (2911)
2012 (2999)
2011 (3155)
2010 (2581)
Location
Africa (92)
Alabama (11)
Alaska (1)
Arizona (12)
Arkansas (2)
Asia (7620)
Australia (886)
California (1092)
Canada (226)
China (169)
Colorado (32)
Connecticut (25)
Delaware (37)
Europe (13883)
Florida (128)
Georgia (18)
Idaho (13)
Illinois (45)
India (11)
Indiana (39)
Iowa (1)
Japan (29)
Kansas (3)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (312)
Massachusetts (744)
Michigan (23)
Minnesota (44)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (437)
New Mexico (4)
New York (304)
North Carolina (193)
North Dakota (7)
Northern California (459)
Ohio (39)
Oklahoma (7)
Oregon (2)
Pennsylvania (183)
Puerto Rico (1)
Rhode Island (5)
South America (134)
South Carolina (2)
Southern California (465)
Tennessee (3)
Texas (140)
Utah (24)
Virginia (15)
Washington D.C. (6)
Washington State (87)
Wisconsin (7)
93,450 Results for "samsung biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.
February 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
January 8, 2025
·
3 min read
Press Releases
Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
January 22, 2025
·
4 min read
Manufacturing
Samsung Biologics Continues Mega-Deal Streak With $1.4B European Contract
The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few months later.
January 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
January 15, 2025
·
4 min read
Press Releases
Samsung Invests in C2N Diagnostics
March 13, 2025
·
4 min read
Press Releases
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
December 3, 2024
·
3 min read
Business
Samsung Biologics Reports First Quarter 2024 Financial Results
Samsung Biologics, a global contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2024.
April 24, 2024
·
4 min read
Press Releases
Samsung Biologics signs manufacturing deal with European pharmaceutical company
November 20, 2024
·
3 min read
Press Releases
Samsung Biologics reports third quarter 2024 financial results
October 23, 2024
·
4 min read
1 of 9,345
Next
